ArticleOcular immunology and inflammation2021
Visual Acuity Outcome over Time in Non-Infectious Uveitis.
Abstract read
In one paragraph
Article in Ocular immunology and inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes.American journal of ophthalmology · 2023Trial
- Characteristics Associated with Appointment No-Show at an Academic Uveitis Service.Ocular immunology and inflammation · 2026Article
- Impact of complications in adult anterior uveitis in a Finnish single-centre registry study.BMJ open ophthalmology · 2025Article
- A Time-Driven Activity-Based Costing Analysis of New Uveitis Patient Visits.Journal of vitreoretinal diseases · 2025Article
- Low Body Mass Index Poses Greater Risk of Primary Open-Angle Glaucoma in African Ancestry Individuals.American journal of ophthalmology · 2025Article
- An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis.Journal of clinical medicine · 2024Article
- Efficacy of golimumab in patients with refractory non-infectious panuveitis.Scientific reports · 2024Article
- Effectiveness of Microinvasive Glaucoma Surgery in the United States: Intelligent Research in Sight Registry Analysis 2013-2019.Ophthalmology · 2023Article
- Long-term visual acuity outcome of pediatric uveitis patients presenting with severe visual impairment.Scientific reports · 2023Article
- Current Landscape of Uveitis Specialists in the United States.Journal of academic ophthalmology (2017) · 2022Article
- Clinical Features of Japanese Patients with Ocular Inflammation and Their Surgical Procedures Over the Course of 20 Years.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Effectiveness of Trabeculectomy and Tube Shunt with versus without Concurrent Phacoemulsification: Intelligent Research in Sight Registry Longitudinal Analysis.Ophthalmology. GlaucomaArticle
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Maxwell PistilliThe Scheie Eye Institute, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-4266-4150
Marshall M JoffeThe Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Sapna S GangaputraDepartment of Ophthalmology and Vision Sciences, Vanderbilt Eye Institute, Nashville, TN, USA.
Siddharth S PujariOm Eye Care Hospital, Belgaum, India.
Douglas A JabsDepartment of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Grace A Levy-ClarkeTampa Bay Uveitis Center, Tampa, FL, USA.
Robert B NussenblattLaboratory of Immunology, National Eye Institute, Bethesda, MD, USA.
James T RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, OR, USA.
H Nida SenLaboratory of Immunology, National Eye Institute, Bethesda, MD, USA.
Eric B SuhlerDepartment of Ophthalmology, Oregon Health and Science University, Portland, OR, USA.
Jennifer E ThorneDepartment of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Nirali P BhattThe Scheie Eye Institute, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
C Stephen FosterMassachusetts Eye Research and Surgery Institution, Cambridge, MA, USA.ORCID 0000-0002-6612-5653
Hosne BegumDepartment of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tonetta D FitzgeraldThe Scheie Eye Institute, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Kurt A DregerThe Scheie Eye Institute, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Michael M AltaweelThe Fundus Photograph Reading Center, University of Wisconsin School of Medicine, Madison, WI, USA.
Janet T HolbrookDepartment of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
John H KempenDepartment of Ophthalmology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2967-4792
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group
Funding
Multi-Center Uveitis Steriod Treatment (MUST) TrialU10EY014660 · NEI · JOHNS HOPKINS UNIVERSITY · PI HOLBROOK, JANET T. · 2004 to 2016
$33.6MScientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI Geoffrey Karl Aguirre · 1985 to 2026
$19.5MADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) TrialUG1EY028091 · NEI · JOHNS HOPKINS UNIVERSITY · PI HOLBROOK, JANET T., SUGAR, ELIZABETH ANN · 2018 to 2022
$9.0MLong-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1MMulticenter Uveitis Steroid Treatment (MUST) TrialU10EY014655 · NEI · JOHNS HOPKINS UNIVERSITY · PI JABS, DOUGLAS A · 2004 to 2016
$4.6MReading Center: Multicenter Uveitis Steroid TrialU10EY014656 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI ALTAWEEL, MICHAEL M · 2004 to 2015
$2.2MIncidence of remission and of cataract in ocular inflammatory diseasesR21EY026717 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI KEMPEN, JOHN H · 2017 to 2018
$495kComplications of Immunosupression for Eye DiseasesR56EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2009 to 2009
$159kNEI NIH HHS P30 EY001583NEI NIH HHS R01 EY014943NEI NIH HHS R21 EY026717NEI NIH HHS R56 EY014943NEI NIH HHS U10 EY014655NEI NIH HHS U10 EY014656NEI NIH HHS U10 EY014660NEI NIH HHS UG1 EY028091
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedFemaleHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesTertiary Health CareTime FactorsUveitisVisual AcuityYoung AdultImmunosuppressive Agentsinverse probability of censoring weightingUveitisVisual acuity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.